Intra-Arterial Tenecteplase After Thrombectomy: Promising but Inconclusive
Ashutosh Jadhav recently shared a post on further management of stroke after successful thrombectomy on X:
”Intra-arterial Tenecteplase for Acute Stroke After Successful Endovascular Therapy.”
Read the full JAMA article here.
A recent study evaluating intra-arterial tenecteplase administered after successful thrombectomy in patients with acute large vessel occlusion (LVO) presenting between 4.5 and 24 hours of symptom onset has shown encouraging yet inconclusive results.
Patients receiving intra-arterial tenecteplase demonstrated a greater likelihood of excellent neurological outcomes at 90 days, without an associated increase in symptomatic intracranial hemorrhage (sICH) or mortality.
However, the optimism was tempered by the fact that none of the secondary efficacy endpoints reinforced the primary findings.
The authors emphasized that further trials are necessary to validate these results and better define the role of intra-arterial tenecteplase in extended-window stroke management.

More on advancements in stroke management featured in Hemostasis Today.
-
Apr 6, 2026, 04:46Ursula Porage Dona: Bringing the Bleeding Disorders Community Together at WFH 2026 with NNHF
-
Apr 6, 2026, 04:17Arun V J: How War Reshaped Blood Transfusion
-
Apr 6, 2026, 03:57Isabella Cieri: How TEG Is Transforming Vascular Surgery Care
-
Apr 5, 2026, 19:00Kausik Ray: Comparing Lipid Management in France vs. Rest of Europe for High Cardiovascular Risk Patients
-
Apr 5, 2026, 18:22Omar Adwan: Systematic Approach to Blood Smear Examination
-
Apr 5, 2026, 18:05Heghine Khachatryan: Rethinking Hemostatic Targets in Pregnancy for von Willebrand Disease
-
Apr 5, 2026, 17:45Matthew Walls: Recognising CAD PRS as a New ‘Risk Enhancing Factor’ in the 2026 ACC/AHA Guidelines
-
Apr 5, 2026, 17:44Philip A. Chan: Occasional Heavy Drinking Leads to 3 Times Higher Liver Fibrosis Risk in MASLD
-
Apr 5, 2026, 17:42Josu de la Fuente: Real World Data Shows Significant Risk of Subsequent HCT in SCD and Thalassemia